CymaBay Therapeutics, Inc. (CBAY) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Sujal A. Shah	President, Chief Executive Officer & Director	1.04M	1973
Klara A. Dickinson-Eason	Chief Regulatory & Quality Assurance Officer	441,836	1968
Paul T. Quinlan	General Counsel, Chief Compliance Officer & Corporate Secretary	629,720	1963
Charles A. McWherter	President of Research & Development and Chief Scientific Officer	700,648	1955
Harish Shantharam	Chief Financial Officer, Principal Accounting & Financial Officer	0	1982
Robert L. Martin	Senior Vice President of Manufacturing & Nonclinical Development	0	1962
Ken Boehm	Senior Vice President of Human Resources	0	N/A
Becki Filice	130494Senior Vice President of Portfolio & Product Leadership	0	1961
Patrick J. O'Mara	Senior Vice President of Business Development	0	1961
Ben Kozub	Head of Commercial	0	N/A

Name

Title

Pay

Year Born

Sujal A. Shah

President, Chief Executive Officer & Director

1.04M

1973

Klara A. Dickinson-Eason

Chief Regulatory & Quality Assurance Officer

441,836

1968

Paul T. Quinlan

General Counsel, Chief Compliance Officer & Corporate Secretary

629,720

1963

Charles A. McWherter

President of Research & Development and Chief Scientific Officer

700,648

1955

Harish Shantharam

Chief Financial Officer, Principal Accounting & Financial Officer

1982

Robert L. Martin

Senior Vice President of Manufacturing & Nonclinical Development

1962

Ken Boehm

Senior Vice President of Human Resources

N/A

Becki Filice

130494Senior Vice President of Portfolio & Product Leadership

1961

Patrick J. O'Mara

Senior Vice President of Business Development

1961

Ben Kozub

Head of Commercial

N/A

Description

CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.